Search

Research

Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies have shown that the nirsevimab binding site is highly conserved. However, investigations of the geotemporal evolution of potential escape variants in recent (ie, 2015–2021) RSV seasons have been minimal.

Research

Food allergy affects up to 10% of Australian infants. It was hypothesized that if parents follow the Australasian Society of Clinical Immunology and Allergy guidelines, Australian food allergy rates may stabilize or decline.

Research

The growing global prevalence of autism spectrum disorder is associated with increasing costs for support services. Ascertaining the effects of a successful preemptive intervention for infants showing early behavioral signs of autism on human services budgets is highly policy relevant.

Read about Professor Tim Jones and Associate Professor Liz Davis, co-directors of the Children's Diabetes Centre.

Browse the published work of the Centre's researchers

Research

RSV hospitalises millions of babies worldwide every year: our research is helping to change that.

While COVID-19 is new and frightening, these resources are designed to help families tackle the challenges this virus has created for us.

Our team aims to optimise lung health early in life to ensure the best possible health outcomes later in life.

The Chronobiology team works to understand the factors that contribute to poor lung and heart function in newborn infants and find ways to prevent heart and lung disease.

The END RHD CRE focuses priority research projects that will help achieve the singular target of producing the Endgame Strategy.